Risperidone vs. Paroxetine for Panic Attacks - Full Text View

Sponsored by:	Beth Israel Medical Center
Information provided by:	Beth Israel Medical Center
ClinicalTrials.gov Identifier:	NCT00206765

Purpose

We are comparing the efficacy of Risperidone versus Paroxetine in the treatment of panic symptoms. The study hypothesis is that Risperidone will be a superior medicine for treating panic.

Condition	Intervention	Phase
Major Depressive Disorder With Panic Attacks Panic Disorder	Drug: Risperidone Drug: Paroxetine	Phase II

MedlinePlus related topics: Depression Panic Disorder

Drug Information available for: Risperidone Paroxetine Paroxetine hydrochloride Paroxetine Mesylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Uncontrolled, Parallel Assignment
Official Title:	A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks

Further study details as provided by Beth Israel Medical Center:

Estimated Enrollment:	90
Study Start Date:	January 2003

Show Detailed Description

Eligibility

Ages Eligible for Study:	21 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males and females, ages 21-55.
Ability to sign an informed consent
Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic
HAM-A score >17

Exclusion Criteria:

Alcohol or substance abuse within the last 6 months
Current diagnosis of Obsessive-Compulsive Disorder
Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder
Use of antipsychotic medications over the two months preceding enrollment in the study
Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study
Previous adverse reaction to risperidone or paroxetine.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00206765

Locations

United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003

Sponsors and Collaborators

Beth Israel Medical Center

Investigators

Principal Investigator:

Igor Galynker, MD, PhD

Beth Israel Medical Center

More Information

Study ID Numbers:	082-02
Study First Received:	September 13, 2005
Last Updated:	April 3, 2007
ClinicalTrials.gov Identifier:	NCT00206765
Health Authority:	United States: Food and Drug Administration

Keywords provided by Beth Israel Medical Center:

panic

Study placed in the following topic categories:

Panic Disorder
Dopamine
Depression
Anxiety Disorders
Mental Disorders
Risperidone

Mood Disorders
Depressive Disorder, Major
Depressive Disorder
Paroxetine
Serotonin
Behavioral Symptoms

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents

Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Antagonists
Pathologic Processes
Serotonin Agents
Therapeutic Uses
Dopamine Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on January 16, 2009